Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL118 in Advanced Pancreatic Ductal Adenocarcinoma
NCT06206876Phase 1Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FL118 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events up to 30 days, Maximum tolerated dose at 4 weeks and 5 more. Planned start Oct 2025; status: withdrawn.
02
Drugs
FL118
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06206876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206876.